Clinical Trials on Relapsed Solid Neoplasm in United Kingdom

Total 67339 results

Sorrento Therapeutics, Inc.

Recruiting

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Solid Tumor | Refractory Tumor | Relapsed Solid Neoplasm

United States
Blueprint Medicines Corporation

Recruiting

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

CNS Tumor | Solid Tumor, Unspecified, Child | Relapsed Solid Neoplasm

United States, Korea, Republic of, United Kingdom, France, Canada, Australia, Austria, Germany, Italy
Royal Marsden NHS Foundation Trust

Recruiting

Improving Informed Consent for Early Phase Anti-Cancer Trials (CONSENT)

Solid Neoplasms

United Kingdom
Leucid Bio

Recruiting

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. (AERIAL)

Tumor, Solid

United Kingdom
AstraZeneca
Quintiles, Inc.

Completed

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase (14C)

Solid Malignancies

United Kingdom
Queen Mary University of London

Recruiting

Tissue Collection Framework To Improve Outcomes In Solid Tumours

Solid Tumours

United Kingdom
Mateon Therapeutics
Cancer Research UK

Completed

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Solid Tumors

United Kingdom
Chugai Pharma Europe Ltd.

Completed

Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors

Solid Tumors

United Kingdom
Hoffmann-La Roche

Completed

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

Solid Tumor

Spain, United Kingdom
LondonPharma Ltd.

Unknown

A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours (LON002-002)

Solid Tumours

United Kingdom
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Advanced Solid Malignancies

United Kingdom
Hoffmann-La Roche

Completed

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

Solid Tumor

United Kingdom, Netherlands
AstraZeneca

Terminated

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

Solid Tumours

United Kingdom
University of Colorado, Denver
University of Kentucky

Completed

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors

United States
GlaxoSmithKline

Completed

SB-715992 In Combination With Docetaxel In Patients With Solid Tumors

Solid Tumor Cancer

United Kingdom
Athenex, Inc.

Completed

Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies

Solid Tumor

United States, United Kingdom
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors (ARQ 197)

Cancer, Advanced Solid Tumors

United Kingdom
AstraZeneca

Completed

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

Advanced Solid Metastatic Tumor

United Kingdom
Stemline Therapeutics, Inc.

Completed

Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors

Advanced Solid Tumor

United Kingdom
Cancer Research UK

Terminated

A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours (AZD0424)

Advanced Solid Tumours

United Kingdom
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

Malignant Solid Tumors

United Kingdom
Chroma Therapeutics

Completed

Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours

Solid Tumor

Netherlands, United Kingdom
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
GlaxoSmithKline

Completed

An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer

Solid Tumours

United Kingdom
Mina Alpha Limited

Active, not recruiting

A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT)

Solid Tumor, Adult

United Kingdom
AstraZeneca
Parexel

Terminated

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Advanced Solid Tumours

United Kingdom, United States
Royal Marsden NHS Foundation Trust
AstraZeneca; Cancer Research UK; RM/ICR Biomedical Research Centre

Active, not recruiting

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot)

Solid Tumour Refractory to Conventional Treatment

United Kingdom
Cephalon

Completed

Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors

Solid Tumor

France, United Kingdom
PharmaMar

Completed

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

Advanced Solid Tumors

United Kingdom, Switzerland
University of Glasgow

Completed

Chemotherapy in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
University of Glasgow

Completed

Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
Heidelberg Pharma AG

Terminated

Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

Advanced Solid Tumours

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
PharmaMar

Completed

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

Specific Advanced Solid Tumors

Spain, United Kingdom
M.D. Anderson Cancer Center

Active, not recruiting

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Cancer Research UK

Terminated

NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
Nerviano Medical Sciences

Terminated

Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

United Kingdom, France
GlaxoSmithKline

Completed

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Solid Tumours

United States, United Kingdom
M.D. Anderson Cancer Center

Terminated

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
AstraZeneca

Active, not recruiting

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Solid Tumors

United Kingdom, Canada
University of Glasgow

Unknown

PNU 166148 in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
Cancer Research UK

Terminated

GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
University of California, San Francisco

Completed

Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Cancer Research UK

Completed

Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
AstraZeneca

Completed

A Study of Tor Kinase Inhibitor in Advanced Tumors

Solid Tumors

United States, France, United Kingdom
National Cancer Institute (NCI)

Completed

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States

Clinical Trials on Relapsed Solid Neoplasm in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations